Page 180 - 80_01

Basilio
Colligris,
Jesús
Pintor

Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment

(CAE) Model (abstract) 2012 ARVO E-Abstract 577/A45.

56. Belimumab. ClinicalTrials.gov Identifier: NCT01160666

http://clinicaltrials.gov/ct2/show/NCT01160666?term=Belimumab+Sjogren&rank=1.

(2012).

57. Cornec D, Saraux A, Devauchelle-Pensec V, et al. The future of B cell-targeted

therapies in Sjogren's syndrome. Immunotherapy. 5(6), 639-46 (2013).

58. Rituximab. ClinicalTrials.gov Identifier: NCT00740948

http://clinicaltrials.gov/ct2/show/NCT00740948?term=Rituximab+Sjogren&rank=1.

(2013).

59. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome

Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in

a randomised controlled trial. Ann Rheum Dis. 73(2), 472-4 (2014).

60. Bartels PS. Use of loteprednol etabonate for the treatment of dry eye.

WO2005094836A2 (2005)

61. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with

loteprednol etabonate. Br J Ophthalmol. 92(4), 455-9 (2008).

62. Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces

cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 27(1), 23-7

(2011).

63. Wan PX, Wang XR, Song YY, et al. (Study on the treatment of dry eye with

Loteprednol Etabonate). Zhonghua Yan Ke Za Zhi. 48(2), 142-7 (2012).

64. Ogawa T, Watanabe N, Okumura Y. Method for preventing or treating dry eye

or disease caused therefrom. US19985830913 (1998)

65. Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive

oxygen species produced by neutrophils after priming with bacterial

lipopolysaccharides. Luminescence. 18(6), 330-3 (2003).

66. Shimoyama T, Fukuda Y, Fukuda S, et al. Ecabet sodium eradicates

Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol. 31 Suppl 9 59-

62 (1996).

67. Zhang JZ, Cavet ME, VanderMeid KR, et al. BOL-303242-X, a novel selective

glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular

cells. Mol Vis. 15 2606-16 (2009).

68. Vollmer TR, Stockhausen A, Zhang JZ. Anti-inflammatory effects of

mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by

MAP kinase phosphatase-1 (MKP-1). J Biol Chem. 287(42), 35212-21 (2012).

69. Schoepe S, Schacke H, Bernd A, et al. Identification of novel in vitro test

systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.

Skin Pharmacol Physiol. 23(3), 139-51 (2010).

70. AL-43546. ClinicalTrials.gov Identifier: NCT00760045

http://clinicaltrials.gov/ct2/show/NCT00760045?term=AL43546&rank=1. (2010).

71. Caballero-Velazquez T, Sanchez-Abarca LI, Gutierrez-Cosio S, et al. The novel

combination of sirolimus and bortezomib prevents graft-versus-host disease but

maintains the graft-versus-leukemia effect after allogeneic transplantation.

Haematologica. 97(9), 1329-37 (2012).

176